CA Patent

CA3131817A1 — Long-acting growth hormone dosage forms with superior efficacy to daily somatropin

Assigned to Ascendis Pharma Endocrinology Division AS · Expires 2020-09-10 · 6y expired

What this patent protects

The present invention relates to a long-acting growth hormone or a pharmaceutical formulation comprising such long-acting growth hormone for use in a method of treating growth hormone deficiency with improved outcomes.

USPTO Abstract

The present invention relates to a long-acting growth hormone or a pharmaceutical formulation comprising such long-acting growth hormone for use in a method of treating growth hormone deficiency with improved outcomes.

Drugs covered by this patent

Patent Metadata

Patent number
CA3131817A1
Jurisdiction
CA
Classification
—
Expires
2020-09-10
Drug substance claim
No
Drug product claim
No
Assignee
Ascendis Pharma Endocrinology Division AS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.